We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
WST raised its 2026 sales and adjusted earnings guidance following robust quarterly results.
West Pharmaceutical Services, Inc. (WST - Free Report) delivered adjusted third-quarter 2026 earnings per share (EPS) of $2.66, which increased 35.7% year over year. The adjustments include restructuring charges and expenses related to M&A activities, among others. The figure surpassed the Zacks Consensus Estimate by 22%.
GAAP EPS for the quarter was $3.02, reflecting an improvement of 57.3% from the year-ago figure.
West Pharmaceutical registered revenues of $874.5 million, up 8.7% year over year. Organic net sales increased 11.9%, driven by robust performance in the Proprietary Products segment, particularly the High-Value Product (“HVP”) Components business. The figure surpassed the Zacks Consensus Estimate by 5.9%.
Shares of WST were up approximately 5.5% in today’s pre-market trading. The company’s shares have gained 46.7% in the year-to-date period compared with the industry’s 11% growth. The S&P 500 Index has risen 12% in the same time frame.
Image Source: Zacks Investment Research
WST's Q3 Segment in Detail
WST operates under two segments: Proprietary Products and West Vantage.
The Proprietary Products segment reported worldwide revenues of $728.8 million, up 12.6% year over year on a reported basis. Organically, revenues increased 16.6%. Our estimate for the segment’s revenues was pinned at $677.2 million.
HVP Components generated sales of $466.7 million, increasing 19.7% year over year. Organic sales grew 20.3%. The business accounted for 53% of total company sales, underscoring its significant contribution to quarterly performance.
HVP Delivery Devices recorded revenues of $99.1 million, flat year over year. However, organic revenues increased 26.4%, excluding foreign currency effects and the SmartDose 3.5mL divestiture impact. Standard Products revenues increased 2.9% to $163 million, reflecting organic growth of 3.1%.
West Pharmaceutical's Vantage Segment Performance
Revenues in the West Vantage segment totaled $145.7 million, down 7.3% from the year-ago quarter’s level. The segment contributed 17% to total company sales. Our estimate for the segment’s revenues was pinned at $147.9 million.
On an organic basis, revenues declined 6.6%. Segment gross profit decreased to $24 million from $30.3 million, while operating profit fell to $15.5 million from $22.3 million.
WST's Market and Geographic Performance
Within Proprietary Products, Biologics revenues increased 15.3% year over year to $379.3 million. Organic sales advanced 23.2%, reflecting strong momentum in this market group.
Pharma revenues climbed 21.3% to $221.3 million, with organic growth of 21.4%. However, Generics revenues declined 5.7% to $128.2 million, while organic sales decreased 4.5%.
Geographically, Asia Pacific delivered the strongest reported growth, with revenues surging 42.4% to $97.1 million. Organic sales increased 41.9%.
Americas revenues rose 6.9% to $401.3 million, while organic growth reached 12.4%. Europe, the Middle East and Africa revenues increased 4.2% to $376.1 million, reflecting organic growth of 5.7%.
West Pharmaceutical's Margin Analysis
In the quarter under review, gross profit increased 18% year over year to $347.4 million. Gross margin expanded 310 basis points (bps) to 39.7%, supported by stronger profitability in Proprietary Products. We had projected a 39.6% gross margin for the third quarter of 2026.
Selling, general and administrative expenses increased 9.9% to $112.9 million. Research and development expenses rose 7% to $18.3 million.
Adjusted operating profit totaled $221.5 million, reflecting a 30.2% improvement from the year-ago quarter’s figure. The adjusted operating margin expanded 420 bps to 25.3%, highlighting improved operating profitability amid strong sales growth. We had projected a 21.3% adjusted operating margin for the third quarter of 2026.
WST's Financial Position
West Pharmaceutical exited the third quarter with cash and cash equivalents of $464.1 million compared with $521.4 million as of the end of the second quarter. Long-term debt was $202.9 million, which remained flat sequentially.
Cumulative net cash provided by operating activities for the first nine months of 2026 was $403.4 million compared with $503.7 million a year ago. Capital expenditures totaled $125 million, down from $209.8 million.
WST repurchased approximately $231 million worth of shares during the quarter, bringing year-to-date repurchases to $685 million. The company also announced an 18% increase in its quarterly dividend to 26 cents per share.
West Pharmaceutical Services, Inc. Price, Consensus and EPS Surprise
West Pharmaceutical raised its full-year 2026 revenue guidance to $3.41-$3.42 billion from the previous projection of $3.345-$3.380 billion.
Management also increased its organic net sales growth outlook to 11.3-11.6% from the earlier expectation of 10-11%.
For 2026, adjusted EPS is now anticipated to be in the range of $9.38-$9.48, up from the previous guidance of $8.85-$9.05. The updated outlook reflects management's confidence following strong third-quarter results.
The company also lowered its full-year capital spending forecast to $215-$220 million from the earlier guidance of $250-$275 million. No additional SmartDose 3.5mL product sales are expected during the remainder of 2026.
Glaukos, sporting a Zacks Rank #1, reported third-quarter 2026 earnings per share of 47 cents, which beat the Zacks Consensus Estimate by 491.67%. Revenues of $211 million surpassed the Zacks Consensus Estimate by 24.99%.
Glaukos has an estimated earnings growth rate of 268.8% for 2027. GKOS’ earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Becton, Dickinson and Company, carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $3.23, which beat the Zacks Consensus Estimate by 2.87%. Revenues of $4.98 billion surpassed the Zacks Consensus Estimate by 1.81%.
Becton, Dickinson and Company has an estimated long-term earnings growth rate of 1.1%. BDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%.
Globus Medical, carrying a Zacks of 2, reported a second-quarter fiscal 2026 adjusted EPS of $1.34, which beat the Zacks Consensus Estimate by 19.6%. Revenues of $790 million missed the Zacks Consensus Estimate by 0.35%.
Globus Medical has an estimated long-term earnings growth rate of 12.4%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%.
View the Zacks #1 Rank List
Image: Bigstock
West Pharma Q3 Earnings Rise on HVP Strength, 2026 Outlook Raised
Key Takeaways
West Pharmaceutical Services, Inc. (WST - Free Report) delivered adjusted third-quarter 2026 earnings per share (EPS) of $2.66, which increased 35.7% year over year. The adjustments include restructuring charges and expenses related to M&A activities, among others. The figure surpassed the Zacks Consensus Estimate by 22%.
GAAP EPS for the quarter was $3.02, reflecting an improvement of 57.3% from the year-ago figure.
West Pharmaceutical registered revenues of $874.5 million, up 8.7% year over year. Organic net sales increased 11.9%, driven by robust performance in the Proprietary Products segment, particularly the High-Value Product (“HVP”) Components business. The figure surpassed the Zacks Consensus Estimate by 5.9%.
Shares of WST were up approximately 5.5% in today’s pre-market trading. The company’s shares have gained 46.7% in the year-to-date period compared with the industry’s 11% growth. The S&P 500 Index has risen 12% in the same time frame.
Image Source: Zacks Investment Research
WST's Q3 Segment in Detail
WST operates under two segments: Proprietary Products and West Vantage.
The Proprietary Products segment reported worldwide revenues of $728.8 million, up 12.6% year over year on a reported basis. Organically, revenues increased 16.6%. Our estimate for the segment’s revenues was pinned at $677.2 million.
HVP Components generated sales of $466.7 million, increasing 19.7% year over year. Organic sales grew 20.3%. The business accounted for 53% of total company sales, underscoring its significant contribution to quarterly performance.
HVP Delivery Devices recorded revenues of $99.1 million, flat year over year. However, organic revenues increased 26.4%, excluding foreign currency effects and the SmartDose 3.5mL divestiture impact. Standard Products revenues increased 2.9% to $163 million, reflecting organic growth of 3.1%.
West Pharmaceutical's Vantage Segment Performance
Revenues in the West Vantage segment totaled $145.7 million, down 7.3% from the year-ago quarter’s level. The segment contributed 17% to total company sales. Our estimate for the segment’s revenues was pinned at $147.9 million.
On an organic basis, revenues declined 6.6%. Segment gross profit decreased to $24 million from $30.3 million, while operating profit fell to $15.5 million from $22.3 million.
WST's Market and Geographic Performance
Within Proprietary Products, Biologics revenues increased 15.3% year over year to $379.3 million. Organic sales advanced 23.2%, reflecting strong momentum in this market group.
Pharma revenues climbed 21.3% to $221.3 million, with organic growth of 21.4%. However, Generics revenues declined 5.7% to $128.2 million, while organic sales decreased 4.5%.
Geographically, Asia Pacific delivered the strongest reported growth, with revenues surging 42.4% to $97.1 million. Organic sales increased 41.9%.
Americas revenues rose 6.9% to $401.3 million, while organic growth reached 12.4%. Europe, the Middle East and Africa revenues increased 4.2% to $376.1 million, reflecting organic growth of 5.7%.
West Pharmaceutical's Margin Analysis
In the quarter under review, gross profit increased 18% year over year to $347.4 million. Gross margin expanded 310 basis points (bps) to 39.7%, supported by stronger profitability in Proprietary Products. We had projected a 39.6% gross margin for the third quarter of 2026.
Selling, general and administrative expenses increased 9.9% to $112.9 million. Research and development expenses rose 7% to $18.3 million.
Adjusted operating profit totaled $221.5 million, reflecting a 30.2% improvement from the year-ago quarter’s figure. The adjusted operating margin expanded 420 bps to 25.3%, highlighting improved operating profitability amid strong sales growth. We had projected a 21.3% adjusted operating margin for the third quarter of 2026.
WST's Financial Position
West Pharmaceutical exited the third quarter with cash and cash equivalents of $464.1 million compared with $521.4 million as of the end of the second quarter. Long-term debt was $202.9 million, which remained flat sequentially.
Cumulative net cash provided by operating activities for the first nine months of 2026 was $403.4 million compared with $503.7 million a year ago. Capital expenditures totaled $125 million, down from $209.8 million.
WST repurchased approximately $231 million worth of shares during the quarter, bringing year-to-date repurchases to $685 million. The company also announced an 18% increase in its quarterly dividend to 26 cents per share.
West Pharmaceutical Services, Inc. Price, Consensus and EPS Surprise
West Pharmaceutical Services, Inc. price-consensus-eps-surprise-chart | West Pharmaceutical Services, Inc. Quote
West Pharmaceutical Raises 2026 Guidance
West Pharmaceutical raised its full-year 2026 revenue guidance to $3.41-$3.42 billion from the previous projection of $3.345-$3.380 billion.
Management also increased its organic net sales growth outlook to 11.3-11.6% from the earlier expectation of 10-11%.
For 2026, adjusted EPS is now anticipated to be in the range of $9.38-$9.48, up from the previous guidance of $8.85-$9.05. The updated outlook reflects management's confidence following strong third-quarter results.
The company also lowered its full-year capital spending forecast to $215-$220 million from the earlier guidance of $250-$275 million. No additional SmartDose 3.5mL product sales are expected during the remainder of 2026.
Zacks Rank & Stocks to Consider
WST currently carries a Zacks Rank #4 (Sell).
Some stocks worth considering from the broader medical space are Glaukos (GKOS - Free Report) , Becton, Dickinson and Company (BDX - Free Report) and Globus Medical (GMED - Free Report) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Glaukos, sporting a Zacks Rank #1, reported third-quarter 2026 earnings per share of 47 cents, which beat the Zacks Consensus Estimate by 491.67%. Revenues of $211 million surpassed the Zacks Consensus Estimate by 24.99%.
Glaukos has an estimated earnings growth rate of 268.8% for 2027. GKOS’ earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Becton, Dickinson and Company, carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $3.23, which beat the Zacks Consensus Estimate by 2.87%. Revenues of $4.98 billion surpassed the Zacks Consensus Estimate by 1.81%.
Becton, Dickinson and Company has an estimated long-term earnings growth rate of 1.1%. BDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%.
Globus Medical, carrying a Zacks of 2, reported a second-quarter fiscal 2026 adjusted EPS of $1.34, which beat the Zacks Consensus Estimate by 19.6%. Revenues of $790 million missed the Zacks Consensus Estimate by 0.35%.
Globus Medical has an estimated long-term earnings growth rate of 12.4%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%.